Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Inhalation Sciences Sweden AB's (publ) ("Inhalation Sciences" or the "Company") Board member Klaus Gottwald has today announced his intention to leave the Company's Board of Directors. The Nomination Committee proposes that Jan Hellqvist be elected as new Board member.
The Company intends to convene an Extraordinary General Meeting where the Nomination Committee proposes that Jan Hellqvist be elected as a new Board member.
"ISAB is undergoing an exciting and important development phase towards becoming the leading global respiratory service organization, supported by PreciseInhale® its unique and patented inhalation platform. I am pleased to welcome Jan Hellqvist to the ISAB Board of Directors and to further benefit from his long experience in respiratory, his extensive pharma service background and importantly his strategic skills in accelerating marketing and sales. I have known Jan both as a co-worker and life science professional for many years and have confidence in that his contribution to ISAB will be of significant importance moving forward. At the same time, I want to emphasize that I am very grateful for Klaus valuable contribution to the Company's Board. His expertise and commitment has always provided guidance and support throughout the Company's journey" says Daniel Spasic, Chairman of the Board of Inhalation Sciences.
"When I was elected to the Company's Board in 2014, the first launch of the Company's PreciseInhale was released. Over the years, the PI-platform has been developed to perfection, and it is with great joy that I can now state that the Company's complete platform for supporting our customers' preclinical inhalation projects is receiving an amazingly positive response from the market" says Klaus Gottwald.
Jan Hellqvist (born 1965) has thirty years of experience within Life Science in Pharmaceuticals, In Vitro Diagnostics, Medical Device and CRO work in Commercial, General Management and CEO positions. Currently Jan is CEO at the Consultancy company Key2Compliance AB. Jan has long experience in respiratory and in building strong consultancy companies within Life Science. Jan is independent from the Company, the company's management, and the Company's major shareholders.
The Extraordinary General Meeting is expected to take place in the autumn of 2022 and a formal notice will be announced in a separate press release. Klaus will remain in his position until a new Board is appointed.